cilengitide has been researched along with Carcinoma, Epidermoid in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Heiduschka, G; Kornek, G; Kotowski, U; Lill, C; Schmid, R; Schneider, S; Seemann, R; Thurnher, D | 1 |
| Bethe, U; Brümmendorf, TH; Clement, PM; Delord, JP; Erfán, J; Gauler, TC; Hicking, C; Iglesias, L; Keilholz, U; Krauss, J; Mesía, R; Peyrade, F; Remenar, E; Schafhausen, P; Vermorken, JB | 1 |
| Atanackovic, D; Barlesi, F; Bennouna, J; Feurer, M; Germonpre, P; Goekkurt, E; Gridelli, C; Hicking, C; Krzakowski, M; Lena, H; Milanowski, J; O'Byrne, K; Picard, M; Schuette, W; Straub, J; Szczesna, A; Vansteenkiste, J; Verhoeven, D; Waller, CF | 1 |
| Boehm, A; Cedra, S; Dietz, A; Hofer, M; Kolb, M; Schlegel, D; Wichmann, G; Wiegand, S | 1 |
| Bier, J; Gath, HJ; Oettle, H; Raguse, JD; Riess, H | 1 |
2 trial(s) available for cilengitide and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Snake Venoms; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2014 |
Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Integrin alphaVbeta3; Lung Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Receptors, Vitronectin; Snake Venoms; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
3 other study(ies) available for cilengitide and Carcinoma, Epidermoid
| Article | Year |
|---|---|
The effect of cilengitide in combination with irradiation and chemotherapy in head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Combined Modality Therapy; Down-Regulation; Humans; Integrins; Otorhinolaryngologic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Snake Venoms; Tumor Stem Cell Assay | 2014 |
Cilengitide and Cetuximab Reduce Cytokine Production and Colony Formation of Head and Neck Squamous Cell Carcinoma Cells
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemokine CCL2; Cytokines; Epithelial Cells; Female; Head and Neck Neoplasms; Humans; Interleukin-6; Male; Middle Aged; Snake Venoms; Squamous Cell Carcinoma of Head and Neck; Vascular Endothelial Growth Factor A | 2017 |
Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Facial Neoplasms; Gemcitabine; Humans; Jaw Neoplasms; Male; Middle Aged; Snake Venoms | 2004 |